Liminatus Pharma, Inc.
LIMN
$3.84
$0.205.35%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -30.34% | 165.29% | 429.14% | 276.79% | 473.14% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 23.31% | 316.69% | 429.14% | 29.11% | 22.99% |
| Operating Income | -23.31% | -316.69% | -429.14% | -29.11% | -22.99% |
| Income Before Tax | -1,342.10% | -243.11% | -3,454.79% | -203.19% | 111.79% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1,342.10% | -243.11% | -3,454.79% | -203.19% | 111.79% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1,342.10% | -243.11% | -3,454.79% | -203.19% | 111.79% |
| EBIT | -23.31% | -316.69% | -429.14% | -29.11% | -22.99% |
| EBITDA | -23.31% | -- | -- | -- | -- |
| EPS Basic | -698.03% | -66.78% | -2,196.05% | -96.46% | 108.85% |
| Normalized Basic EPS | 46.34% | -66.78% | -182.43% | -156.79% | 0.53% |
| EPS Diluted | -698.03% | -66.78% | -2,196.05% | -96.46% | 108.85% |
| Normalized Diluted EPS | 46.34% | -66.78% | -182.43% | -156.79% | 0.53% |
| Average Basic Shares Outstanding | 107.73% | 105.71% | 54.86% | 54.34% | 33.14% |
| Average Diluted Shares Outstanding | 107.73% | 105.71% | 54.86% | 54.34% | 33.14% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |